文献速递肾小球疾病

狼疮性肾炎试验设计与终点的系统评价

Systematic Review of Trial Design and End Points in Lupus Nephritis.
PubMed 文献 · Kidney Int Rep · 2026-03-10

INTRODUCTION: Advances in our understanding of immune dysregulation in lupus nephritis (LN) are driving a surge in the development of targeted pharmaceutical agents for a disease that continues to carry a high rate of morbidity and mortality.…

要点

  • 狼疮性肾炎试验设计异质性大,影响疗效比较。
  • 入组者基线肾功能较高,平均基线eGFR中位数95 ml/min/1.73 m2。
  • 建议采用专家共识指南标准化未来狼疮性肾炎研究。

核心结论

  • 当代狼疮性肾炎试验在设计关键要素和报告方面存在显著异质性,阻碍了新疗法疗效的公平比较。

主要发现

  • 入组者基线肾功能较高,平均基线eGFR中位数为95 ml/min/1.73 m2。
  • 活动性疾病定义存在差异,肾功能变异性高,且治疗反应定义基于糖皮质激素。

关键数值与推荐

  • 共评估15项随机对照试验,其中4项证明研究药物优于标准治疗。

临床怎么用

  • 建议采用专家提出的指南集来帮助标准化未来狼疮性肾炎研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Advances in our understanding of immune dysregulation in lupus nephritis (LN) are driving a surge in the development of targeted pharmaceutical agents for a disease that continues to carry a high rate of morbidity and mortality. Although meaningful progress is being made in the management of LN, the substantial heterogeneity in critical elements of trial design and reporting that exists across contemporary LN trials hampers our ability to fairly compare the efficacy of new therapies. METHODS: In this review, we comprehensively summarized and compared end points, various aspects of methodology (including glucocorticoid usage and eligibility criteria), actual trial population, and results reporting across studies published in the last 2 decades. We assessed 15 phase 2/3, interventional, randomized controlled trials (RCTs), of which 4 demonstrated the superiority of the investigational agent over standard therapy. RESULTS: Emerging themes comprise the inclusion of participants with high median baseline kidney function (median of the average baseline estimated glomerular filtration rate (eGFR) was 95 ml/min per 1.73 m2), differences in definitions of active disease, high variability in kidney function, and glucocorticoid-based definitions of treatment response. CONCLUSION: Based on the findings of this review, we suggest a set of expert-posited guidelines to help in standardizing future studies in LN.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Giang S, Dall'Era MA, Jones RB, et al. Systematic Review of Trial Design and End Points in Lupus Nephritis. Kidney Int Rep. 2026. PMID: 42006208. doi:10.1016/j.ekir.2026.106479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。